Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun 19;17(1):439.
doi: 10.1186/s12879-017-2550-2.

Antiretroviral therapy initiation within seven days of enrolment: outcomes and time to undetectable viral load among children at an urban HIV clinic in Uganda

Rogers Ssebunya  1 , Rhoda K Wanyenze  2 , Heather Lukolyo  3 , Milton Mutto  2 , Grace Kisitu  3 , Pauline Amuge  3 , Albert Maganda  3 , Adeodata Kekitiinwa  3
Affiliations

Antiretroviral therapy initiation within seven days of enrolment: outcomes and time to undetectable viral load among children at an urban HIV clinic in Uganda

Rogers Ssebunya et al. BMC Infect Dis. .

Abstract

Background: Viral suppression is a critical indicator of HIV treatment success. In the era of test-and-start, little is known about treatment outcomes and time to undetectable viral loads. This study compares treatment outcomes, median times to achieve undetectable viral loads and its predictors under different antiretroviral (ART) treatment initiation schedules (i.e. within seven days of enrolment or later).

Methods: A retrospective cohort of 367 patients <18 years who enrolled in care between January 2010 and December 2015 with a baseline viral load of >5000 copies/ml were followed up for 60 months. Undetectable viral load measurements were based on both Roche (<20copies/ml) and Abbot (<75copies/ml). Clinical treatment outcomes were compared using chi-squared test. Survival experiences between the two cohorts were assessed through incidence rates and Kaplan Meier curves. A cox model with competing risks was used to assess predictors for time to undetectable viral load.

Results: Of the 367 patients, 180 (49.1%) initiated ART within seven days from enrolment, 192 (52.3%) attained undetectable viral load of which 133 (69.3%) were children below six years and 101 (52.6%) were females. Among those who initiated ART within seven days 15 (8.3%) died and 6 (3.3%) were lost to follow-up compared to 27 (14.4%) and 16 (8.6%) respectively in the later initiators. The median time to undetectable viral load was 24.9 months (95% CI: 19.7, 28.5) among early ART initiators and 38.5 months (95% CI: 31.1, 44.5) among those initiating beyond seven days. There was a significant difference in failure estimates between those initiating within seven and those that deferred (log rank, p = 0.001). Significant predictors for time to undetectable viral load were; starting ART within seven days (SHR = 2.02, 95% CI: 1.24, 3.28), baseline WHO stage I or II (SHR = 1.59, 95% CI: 1.06, 2.28), inconsistent adherence on three consecutive clinic visits (SHR = 0.44, 95% CI: 0.28, 0.67), and baseline weight (SRH = 1.04, 95% CI: 1.01, 1.07).

Conclusion: Prompt initiation of ART within the first week of enrolment is associated with better treatment outcomes. Early timing, baseline WHO clinical stage and adherence rates should be major considerations while managing HIV among children.

Keywords: Antiretroviral therapy; HIV; Outcomes; Timing; Undetectable viral load.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan Meier curves showing failure experiences of patients initiated on ART within and beyond 7 days of enrolment
See this image and copyright information in PMC

References

    1. UNAIDS, Global AIDS update 2016. http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update... Accessed 15 July 2016.
    1. WHO, Accelerating progress on HIV, Tuberculosis, Malaria, Hepatitis and neglected tropical diseases. A new Agenda for 2016–2030. http://www.who.int/about/structure/organigram/htm/progress-hiv-tb-malari.... Accessed 21 June 2016.
    1. Montaner, J.S.G., Lima VD, Barrios R, Yip B, Wood E, Kerr T et al., Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. The Lancet. 376(9740): p. 532–539. - PMC - PubMed
    1. WHO, Antiretroviral Treatment as Prevention (TasP) of HIV and TB. 2012. http://www.who.int/hiv/pub/mtct/programmatic_update_tasp/en/. Accessed 21 June 2016.
    1. HIV-CAUSAL Collaboration, Ray M, Logan R, Sterne JA, Hernández-Díaz S, Robins JM, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (London, England), 2010. 24(1): p. 123–137. - PMC - PubMed

Substances